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The prognosis of acute myeloid leukemia (AML), parti-
cularly when associated with adverse chromosomal or
molecular aberrations, is poor due to a high relapse rate
after induction chemotherapy. Postremission therapy for
elimination of minimal residual disease remains a major
challenge. Immunotherapeutic strategies aim at the
stimulation of AML-specific immunity, especially of
CD8+ T cells. However, the functionality of these cells
in AML patients is not well described. T cell exhaustion
has been suggested to contribute to immune evasion in
various solid and haematological malignancies. Primarily
demonstrated in chronic viral infections, exhausted
T cells are characterised by an increased expression of
several inhibitory molecules, reduced proliferation and an
impaired capability of cytokine secretion and cytotoxicity.
To characterise T cell exhaustion in AML, we assessed
the phenotype and effector function of CD8+ and CD4+
T cells by flow cytometry. T cells from patients at primary
diagnosis, with refractory disease, at relapse and at relapse
after allogeneic stem cell transplantation (alloSCT) were
analysed for surface expression of CD244, CD160, PD-1,
TIM-3 and LAG-3. T cell proliferation and production of
the cytokines IFN-g, TNF-a and IL-2 were measured in
response to different stimuli. Results were compared to
healthy controls (HCs), while untreated HIV-infected
patients served as positive controls for an exhausted T cell
state.
In HIV-infected patients, we observed a pronounced
upregulation of the inhibitory molecules CD244, CD160
and PD-1 on CD4+ and CD8+ T cells as well as globally
impaired cytokine production, clearly indicating T cell
exhaustion. In contrast, T cells from AML patients showed
an expression pattern of inhibitory surface molecules
that was similar to T cells from age-matched HCs. AML
patients with a relapse after alloSCT, however, showed
remarkably high PD-1 expression on CD4+ and CD8+
T cells, accompanied by a shift from naive to memory
T cells. Functionally, no defect in T cell proliferation in any
of the AML patient cohorts was detected. Of note, however,
we observed a 2-fold decrease in IFN-g production by CD4+
T cells exclusively in patients at primary diagnosis.
Thus, T cells of AML patients are fully functional.
Immunotherapies that aim at eliciting tumour-specific
immune responses, e.g. dendritic cell based vaccines, may
therefore be particularly suited for AML treatment.
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